Axsome Therapeutics Inc (AXSM)

70.84
-3.90(-5.22%)
After Hours
71.20
+0.36(+0.51%)
- Real-time Data
  • Volume:
    2,929,090
  • Day's Range:
    70.40 - 75.98
  • 52 wk Range:
    20.63 - 79.40
Unusual trading volume

Axsome Therapeutics Inc has doubled (or more) its daily average of shares traded over the last 3 months. High volumes usually indicate new trends and larger share price movements.

AXSM Overview

Prev. Close
74.74
Day's Range
70.4-75.98
Revenue
25.67M
Open
75.5
52 wk Range
20.63-79.4
EPS
-4.08
Volume
2,929,090
Market Cap
3.08B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,452,380
P/E Ratio
-13.78
Beta
1.75
1-Year Change
102.44%
Shares Outstanding
43,426,162
Next Earnings Date
Mar 16, 2023
What is your sentiment on Axsome Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Axsome Therapeutics Inc News

Axsome Therapeutics Inc Analysis

Axsome Therapeutics Inc Company Profile

Axsome Therapeutics Inc Company Profile

Employees
108

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Read More

Analyst Price Target

Average108.87 (+53.68% Upside)
High210
Low35
Price70.84
No. of Analysts15
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellSellBuyStrong BuyStrong Buy
Technical IndicatorsStrong SellStrong SellStrong BuyStrong BuyStrong Buy
SummaryStrong SellStrong SellStrong BuyStrong BuyStrong Buy
  • Great call on this one by the Analysts.
    0
    • never a stock like this!!
      0
      • Offering soon?
        0
        • Sidus Space Signs MOU with Exo-Space to Support Edge Computing Technology
          0
          • Advise to buy more ??!!
            0
            • OPA??
              0
              • FDA positive news?
                0
                • What
                  0
                  • Slowly
                    0
                    • Time to buy today
                      1